XOMA Announces Pricing of $39.2 Million Public Offering of Common Stock and Warrants Mar 06, 2012 9:00am EST
XOMA Acquires U.S. Rights to Perindopril Franchise and Establishes Commercial Operations Jan 17, 2012 4:05pm EST
XOMA Initiates Gevokizumab Phase 2 Study for Moderate to Severe Acne Vulgaris Dec 21, 2011 8:00am EST
